What the HHS policy opened
A compounding pharmacy, the kind that mixes a medication for one patient on a prescription, can normally only use ingredients the federal rules allow. The official list is called the 503A Bulks List, and BPC-157 still isn't on it. What changed in October is enforcement, not the list.
| Step | What it is | Where it stands |
|---|---|---|
| July 23 vote | Advice from an FDA panel | Recommended 8 to 6 |
| October 28 policy | HHS enforcement policy | Published, conditional draft |
| 503A Bulks List | The law itself | BPC-157 not added |
The July panel vote was advice and bound nobody. The Department of Health and Human Services (HHS) posted its policy on October 28, and its notice in the Federal Register, the government's daily record of rules, on October 30 says HHS "does not intend to take enforcement action" against state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157 and five other peptides. It calls itself a draft that "is not binding on HHS or the public."
What it takes
The full policy sits in a separate HHS document we couldn't open, so the conditions here come from two legal readings, Baker Hostetler's and the FDA Law Blog's. Per both, the pharmacy or physician has to work from a valid prescription for an individual patient, make a product with BPC-157 as its single active ingredient, buy the raw peptide from an establishment registered with the FDA, and report serious adverse events and quality problems to the FDA's MedWatch program. The FDA Law Blog lists BPC-157 as covered whether it's injected under the skin or into a muscle, taken by mouth, or applied to the skin.
So the route looks like this. A licensed prescriber writes the order for you, a state-licensed compounding pharmacy agrees to make it, and your state's pharmacy board allows it. That last part is the open question, and the FDA Law Blog notes it's unclear whether state boards will follow the federal lead. Some pharmacies may wait to see how their board reads the policy before they start, so ask the pharmacy directly.
What it doesn't change
It doesn't approve BPC-157, and compounded drugs stay unapproved, which means the FDA doesn't review them for safety, effectiveness or quality before they're sold. Baker Hostetler says the policy doesn't cover the large outsourcing facilities known as 503B, or products sold as research chemicals or dietary supplements. HHS can revisit it "if, among other things, a safety signal or product quality issue arises," and making BPC-157 permanent would still take formal rulemaking to add it to the list, which can take years.
Not everyone wants it. The Partnership for Safe Medicines had already filed a formal petition asking the FDA not to allow it, and Public Citizen criticized the policy the day it came out. The public comment window runs into mid-November. Our write-up of the published policy has the full picture, and the guide to whether peptides are legal right now sorts the law, the vote and the policy apart.
What it means for you right now
If you want the pharmacy route, start with a prescriber who'll write it and a pharmacy that confirms it's compounding BPC-157 under the policy. A clinic or seller offering compounded BPC-157 with no prescription for you is outside the policy, and that's a reason to ask more questions of them, not fewer.
Research-use vendors are a separate channel, and on Baker Hostetler's reading the policy doesn't reach it. We track 50 vendors with a live BPC-157 listing, and on that side the checks that matter haven't changed: the vendor and the batch. The vendor directory shows how each one is vetted, our guide to reading a certificate of analysis (COA) covers the lab report, the BPC-157 page covers what people use it for, and is BPC-157 legal has the wider legal picture.
For what a full course costs, see how much BPC-157 costs.
BPC-157 is sold for research, it isn't FDA approved, and the big human trials haven't been run yet. You knew that, it's why you're reading this and not the label.
Questions people ask
Do you need a prescription for BPC-157?
From a compounding pharmacy, yes. The HHS policy covers products made for an individual patient on a valid prescription, as Baker Hostetler and the FDA Law Blog read it. Research-use vendors sell BPC-157 without one, labeled for research and not for human use.
Can compounding pharmacies make BPC-157?
BPC-157 still isn't on the 503A Bulks List, the law's list of allowed ingredients. Since October 28, 2026, HHS has said it won't act against state-licensed pharmacies that compound it under set conditions, which is enforcement discretion rather than a change in the law.
How do I get BPC-157 prescribed?
The route is a licensed prescriber's order for you, filled by a state-licensed compounding pharmacy that buys the raw peptide from an FDA-registered source and meets the policy's other conditions. Ask the pharmacy directly whether it's compounding BPC-157 and in which forms, since availability will vary by state and pharmacy.
When will BPC-157 be available at pharmacies?
HHS posted the policy on October 28, 2026, but pharmacies decide for themselves whether to offer it, and some may wait to see how their state board reads the policy. Expect it to vary by state for a while.
Can a telehealth clinic prescribe BPC-157?
A licensed prescriber, including one working through a telehealth clinic, can write the order, and under the HHS policy a state-licensed compounding pharmacy can fill it if it meets the conditions. A clinic or seller offering BPC-157 with no prescription for you falls outside the policy.
